Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease

Respiration

Volumn 73, Issue 5, 2006, Pages 603-609

  Paggiaro, Pierluigi L ^a,c   Vagaggini, B ^a   Di Franco, A ^a   Zingoni, M ^a   Fano, M ^b   Biraghi, M ^b  

^a UNIVERSITY OF PISA   (Italy)

^b Medical Direction   (Italy)

^c CISANELLO HOSPITAL   (Italy)

Author keywords

Chronic obstructive pulmonary disease; Exacerbations; Flunisolide; Inhaled corticosteroids; Ipratropium bromide; Nebulizer; Salbutamol

Indexed keywords

CORTICOSTEROID; FLUNISOLIDE; IPRATROPIUM BROMIDE; SALBUTAMOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEBULIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SKIN MANIFESTATION; SPUTUM; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY; TACHYCARDIA;

AGED; ALBUTEROL; ANTI-ASTHMATIC AGENTS; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUOCINOLONE ACETONIDE; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; TREATMENT OUTCOME;

EID: 33749254047     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000089816     Document Type: Article

References (32)

1. Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report. Bethesda, National Institutes of Health, 2001, NIH Publ 2701.
2. Murray CJL, Lopez AD (eds): The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries and risk factors in 1990 and projected to 2020. Cambridge, Harvard University Press, 1996.
3. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B: The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002;96:700-708.
4. Aaron SD, Angel JB, Lunau M, Wright K, Fex C, Le Saux N, Dales R: Granulocyte inflammatory markers and airway infection during acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:349-355.
5. Patel IS, Seemungal TAR, Wilks M, Lloyd-Owen SJ, Donaldson GC, Wedzicha JA: Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 2002;57:759-764.
6. Seemungal TAR, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA: Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-1422.
7. Donaldson GC, Seemungal TAR, Bhowmik A, Wedzicha JA: Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002;57:847-852.
8. Connors AF, Dawson NV, Thomas C, Harrell FE, Desbiens N, Flukerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA, for the SUPPORT investigators: Outcomes following acute exacerbation of severe chronic obstructive lung disease. Am J Respir Crit Care Med 1996;154:959-967.
9. 1 decline in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1090-1095.
10. Paggiaro PL: Does early treatment of exacerbation improve outcome in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 2004;169:1267-1272.
11. Paggiaro PL, Dahle R, Bakran I, Frith K, Hollingworth K, Efthimiou J: Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998;351:773-780.
12. Alsaedi A, Sin DD, McAlister FA: The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med 2002;113:59-65.
13. 2 agonists study group: combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456.
14. Jones PW, Willits LR, Burge PS, Calverly PM, Inhaled Steroids in Obstructive Lung Disease in Europe study investigators: Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003;21:68-73.
15. Siafakas NM, Vermeire P, Pride NB, et al: Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J 1995;8:1398-1420.
16. Anthonisen NR, Manfreda J, Warren CPW, Hershfield ES, Harding GKM, Nelson NA: Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987;106:196-204.
17. Singh SJ, Morgan MDL, Scott S, Walters D, Hardman AE: Development of a shuttle walking test of disability in patients with chronic airway obstruction. Thorax 1992;47:1019-1024.
18. Jones PW, Quirk FH, Baveystock CM, Littlejohns P: A self-complete measure for chronic airflow limitation - the St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-1327.
19. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H: Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
20. Calverly PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H: Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919.
21. Barta SK, Crawford A, Roberts CM: Survey of patients' views of domiciliary nebuliser treatment for chronic lung disease. Respir Med 2002;96:375-381.
22. Melani AS, Sestini P, Aiolfi S, Barbato N, Canessa P, De Angelis G, Zanchetta D, De Tullio R, Cinti C, Neri M, Associazione Italiana Pneumologi Ospedalieri (AIPO) Educational Group: GENebu Project: home nebulizer use and maintenance in Italy. Eur Respir J 2001; 18:758-763.
23. Cook D, Guyatt G, Wong E, Goldstein R, Berard M, Austin P, Ramsdale H, Jaeschke R, Sears M: Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;163:85-90.
24. Ramsey SD: Suboptimal medical therapy in COPD: exploring the causes and consequences. Chest 2000;117(2 suppl):33S-37S.
25. Beeh KM, Welte T, Buhl R: Anticholinergics in the treatment of chronic obstructive pulmonary disease. Respiration 2002;69:372-379.
26. Hay JG, Stone P, Carter J, Curch S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverly PMA: Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-664.
27. Patakas D, Andreadis D, Mavrofridis E, Argyropoulou P: Comparison of the effects of salmeterol and ipratropium bromide on exercise performance and breathlessness in patients with stable chronic obstructive pulmonary disease. Respir Med 1998;92:1116-1121.
28. Grove A, Lipworth BJ, Reid P, Smith RP, Ramage L, Ingram CG, Jenkins RJ, Winter JH, Dhillon DP: Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996;51:689-693.
29. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW: Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled. 3-month trial. Eur Respir J 2002;19:936-943.
30. Jones PW, Bosh TK, in association with an international study group: Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997;155:1283-1289.
31. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ, on behalf of the Dutch/Belgian Tiotropium Study Group: Improved outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002;19:209-216.
32. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C: Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. The COPE study. Am J Respir Crit Care Med 2002;166:1358-1363.